News
Neurovalens shines at the 2024 Life Science Industry Awards
We are delighted to have been awarded the Small Life Science Company of the Year at the 2024 Life Science Industry Awards, held in Dublin on the 27th of June. The event recognised the most innovative individuals and companies leading excellence in Ireland's life sciences sector.
Meet The Team - Richard Barnes - Software QA Analyst
I'm Richard Barnes and I joined Neurovalens in May 2021. I'm a Software QA Engineer and my role in the company is to test our iOS and Android apps to ensure they work as well as they can, both in terms of being bug-free and user-friendly.
Neurovalens Appoints Kate Willis as Vice President of Commercialization
Kate Willis has been appointed as the Vice President of Commercialization, where she will oversee the sales of Neurovalens' prescribed medical devices in the US and work towards securing reimbursement approvals from private healthcare insurance providers.
Meet The Team - Rebecca Armstrong - Clinical & Quality Manager
My name is Rebecca Armstrong, I am the Clinical and Quality Manager at Neurovalens. I joined Neurovalens in September 2022 and have been involved in setting up and managing a fully remote PTSD trial, establishing the Quality Management System (QMS), and successfully guiding the company through the ISO 13485 audit.
We're Hiring: Logistics Associate
Neurovalens is looking for an enthusiastic Logistics Associate to join our passionate and hard working team. This an exciting time for an ambitious individual to consider a career at Neurovalens.
Neurovalens CEO Appointed Visiting Scholar at UC San Diego
Neurovalens CEO, Dr. Jason McKeown has been appointed as a Visiting Scholar at the prestigious University of California, San Diego (UCSD), joining the Department of Psychiatry. This appointment marks a journey that began nearly a decade ago when Jason first collaborated with UCSD.
Neurovalens receives FDA clearance for medical device to treat anxiety
Modius Stress becomes company’s second product cleared for use in US. Neurovalens, a global leader in non-invasive neuro-technology, has received medical device clearance from the US Food & Drug Administration (FDA) to treat anxiety with its Modius Stress device
Celebrating Success: Neurovalens Triumphs at Digital DNA Awards 2024
Neurovalens were delighted to be awarded two recognitions at the 2024 Digital DNA awards in Belfast’s ICC, Waterfront on Thursday, March 21st. Small Tech Company of the Year and Highly Commended in the Tech For Good category.
Iain Hendrick (CPO) Joins the Shott Scale Up Accelerator Cohort for 2024
Building a high-performance team requires high performance leadership. Our Chief Project Officer, Iain Hendrick, will be spending the next 12 months on the Shott Scale Up Accelerator program with the Royal Academy of Engineering.
Meet The Team - John Conway - Logistics Coordinator
Joining Neurovalens was a no-brainer for me! I loved the idea of working for a company that was trying to help people. I also had an interest in the brain for as long as I can remember...
Meet The Team - Sinead Watson - Head of Clinical & Regulatory
My name is Sinead Watson, and I joined Neurovalens in September 2022. My role at Neurovalens is Head of Clinical & Regulatory that involves leading the clinical team in the planning, execution and delivery of several clinical trials and regulatory submissions.
UK Innovation at Arab Health
Neurovalens were delighted to take our FDA Cleared Modius Sleep technology to Arab Health 2024, a Global Healthcare Medical Expo in Dubai from 29th January to 1st February 2024.
